Medical Device Division, Innovation and Business Development Headquarters, Daicel Corporation, Minato-ku, Tokyo 108-8230, Japan.
Analyst. 2020 May 7;145(9):3211-3216. doi: 10.1039/c9an02514f. Epub 2020 Apr 3.
We developed an in vitro chromophore-solid phase peptide reaction assay (C-SPRA) using microbead-immobilized peptides and chromophores. Peptide-resins (microbeads) reacted with 14 representative chemicals to demonstrate the test's capacity to predict skin sensitization. C-SPRA enables accurate and high-throughput assessments of various chemicals, including poorly water-soluble sensitizers that are regarded as weakly potent by other methods.
我们开发了一种使用微珠固定化肽和生色团的体外生色固相肽反应测定法(C-SPRA)。肽树脂(微珠)与 14 种代表性化学物质反应,以证明该测试预测皮肤致敏的能力。C-SPRA 能够对各种化学物质进行准确和高通量的评估,包括被认为是其他方法弱效的水溶性差的敏化剂。